Aim ImmunotechAIM
13F holders, Q2 2026 (June 30)18holders
4new positions
3sold out
$0.28avg. 13F price*
At the end of Q2 2026, 18 institutions reported holding Aim Immunotech Inc. (AIM) in their 13F filings, unchanged from Q1 2026. 4 opened new positions and 3 sold out. The largest holders were Jane Street Group, LLC ($229K), Virtu Financial LLC ($35K) and Morgan Stanley ($14K).
- Company
- Aim Immunotech Inc.
- CUSIP
- 00901B303
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $19K |
| Exits | 3 | $30K |
All 13F filers, Q1 2026 → Q2 2026: 1,023,252 shares bought and 51,624 shares sold, net +971,628 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Jane Street Group, LLC | 0.00% | Add +3929.9% | 807,885 | $229K |
| Virtu Financial LLC | 0.00% | Add +144.2% | 124,269 | $35K |
| Morgan Stanley | 0.00% | Add +5787.0% | 50,864 | $14K |
| Geode Capital Management, LLC | 0.00% | Add +53.8% | 46,003 | $13K |
| Goldman Sachs Group Inc. | 0.00% | New | 32,444 | $9K |
| UBS Group AG | 0.00% | Add +2893000.0% | 28,931 | $8K |
| Susquehanna International Group, LLP | 0.00% | New | 21,859 | $6K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 17,519 | $5K |
| Ground Swell Capital, LLC | 0.00% | New | 12,222 | $3K |
| Tower Research Capital LLC (TRC) | 0.00% | No change | 4,668 | $1K |
| Continuum Advisory, LLC | 0.00% | New | 500 | $142 |
| Community Bank, N.A. | 0.00% | No change | 132 | $36 |
| Harbour Investments, Inc. | 0.00% | No change | 32 | $9 |
| Creative Financial Designs Inc. | 0.00% | No change | 30 | $9 |
| Osaic Holdings, Inc. | 0.00% | No change | 15 | $3 |
| Hoey Investments, Inc. | 0.00% | No change | 10 | $3 |
| Farther Finance Advisors, LLC | 0.00% | No change | 1 | $0 |
| Intesa Sanpaolo Wealth Management | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is AIM's weight in each manager's 13F, not the share of Aim Immunotech Inc. the manager owns.